Intradigm | GenomeWeb

Intradigm

For the six-month period ended June 30, Silence's net loss rose to ₤7.05 million ($11 million) from ₤3.57 million in the year-ago period.

Silence said that as a result of the consolidation, it has laid off about 20 staffers, primarily in research and development.

The companies touted the financial benefits of the transaction, but it appears that the establishment of a broad drug-delivery portfolio attractive to prospective big pharma partners was the primary driver of the deal.

The change follows a number of false starts RXi has made in regard to its pipeline, as well as the firm’s failure to meet previously stated partnering goals. But RXi is not alone in this respect, and management changeups in troubled times have been par for the course among RNAi drug shops.

While most companies working in the RNAi drugs field have been able to secure the money needed to maintain operations, a number of players in the space have bowed out under unfavorable circumstances.

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.